Doxorubicin toxicity on pulmonary tissue

Abstract

 A variety of malignancies can be effectively treated with doxorubicin. It is mostly used to treat leukemias, lymphomas, and a variety of solid cancers, including thyroid, breast, lung, and ovarian cancer. Doxorubicin exhibits dose-dependent cytotoxicity, which is especially harmful to the heart, just as other anti-cancer drugs. As an anthracycline, doxorubicin is an antibiotic that has been researched for many years and is utilized as a cytostatic medication in lung cancer treatment. This study aims to identify damage to lung tissue due to the impact of different doses of doxorubicin. Male albino rats, which weighed between 200 and 250 grams. Laboratory animals were obtained from the Technology Research Center, University of Nahrain, and laboratory rats were bred at the University of Baghdad, College of Science, Department of Biology, Animal House. Three sets of six male rats were used in the investigation.  Normal saline was given to Group 1, doxorubicin at a dose of 5 mg/kg body weight was administered intraperitoneally twice a week for four weeks to Group 2, and doxorubicin at a dose of 10 mg/kg body weight was administered intraperitoneal twice a week for four weeks to Group 3. 4% formaldehyde was used to fix the lung tissues for histopathological analysis. Histopathological analysis revealed various effects on the lung tissues. The laboratory animal dosing period is from 2/1/2025 to 3/1/2025 for 4 weeks.

In the sections from rats treated with doxorubicin (5 mg/kg body weight), acute pulmonary hemorrhage, diffuse pulmonary emphysema, and pulmonary edema were observed. Conversely, the sections from the rats treated with doxorubicin (10 mg/kg body weight) displayed signs of acute lung necrosis, acute lung abscess, and hemorrhagic infarction